The Battle Against Drug Price Gouging: A New Era of Accountability
The recent $11 million settlement between the North Carolina Attorney General’s Office and Mylan, the distributor of EpiPen, signals a pivotal shift in how states handle pharmaceutical pricing. For years, life-saving medications have seen astronomical price hikes that leave patients choosing between their health and their financial stability.
In the case of the EpiPen, North Carolina Attorney General Jeff Jackson highlighted a staggering increase, noting that the price for a two-pack surged from $100 to $600
between 2007 and 2016. This is not an isolated incident, but rather a symptom of a broader systemic issue within the pharmaceutical industry known as price gouging.
price gougingin pharmaceuticals often occurs when a company holds a monopoly on a life-saving drug and raises prices far beyond the cost of production, knowing that consumers have no other choice but to pay.
As state governments become more aggressive in pursuing these settlements, we are seeing a trend toward greater transparency. The goal is no longer just a one-time payout, but a fundamental change in how drugs are priced and distributed to ensure that out-of-pocket costs will be lower going forward
, as stated by AG Jackson.
Breaking the “Patent Thicket”: The Future of Generic Access
One of the most contentious issues in healthcare is the use of the patent system to stifle competition. Pharmaceutical companies often employ a strategy called evergreening
or creating patent thickets
.
What is “Evergreening”?
Evergreening occurs when a company makes slight, non-therapeutic changes to a drug—such as changing the delivery mechanism or the dosage form—to secure a new patent just as the old one is about to expire. This prevents cheaper generic versions from entering the market.
The North Carolina settlement specifically addressed this, with AG Jackson asserting that Mylan used the patent system to delay competitors from getting to the market
. When competition is blocked, the original manufacturer maintains a monopoly, allowing them to dictate prices without the pressure of a cheaper alternative.
Future trends suggest a legislative push toward patent reform. Lawmakers are increasingly exploring ways to limit the number of patents that can be filed for a single drug, which would accelerate the arrival of generics and biosimilars—essentially the “generic” versions of complex biological drugs.
Beyond Settlements: Systemic Shifts in Medication Affordability
While state-level lawsuits provide immediate relief, the broader trend is moving toward federal intervention and systemic pricing overhauls. We are seeing a transition from reactive lawsuits to proactive regulation.
A primary example of this shift is the Inflation Reduction Act (IRA) in the United States, which for the first time allows Medicare to negotiate prices directly with manufacturers for some of the most expensive drugs. This mirrors the intent of the North Carolina settlement: reducing the financial burden on taxpayers and the most vulnerable populations.
Patient Assistance Programs (PAPs)offered by manufacturers or use pharmacy discount tools like GoodRx to find the lowest available price in your area.
the rise of “cost-plus” pharmacy models is challenging the traditional PBM (Pharmacy Benefit Manager) system. By charging a flat fee plus a small percentage of the drug’s actual cost, these models eliminate the hidden markups that often drive up the price of medications like epinephrine.
The Ripple Effect: How State Actions Influence National Policy
When a state like North Carolina successfully holds a pharmaceutical giant accountable, it creates a blueprint for other states. The $11 million settlement, which allocates $4.2 million each to the state health plan and North Carolina Medicaid, demonstrates that legal action can result in direct financial recovery for public health systems.
This “domino effect” puts other drug companies on notice. As AG Jackson noted, the intent is to set a precedent: If we have evidence they are breaking the law, we are going to hold them accountable.
As more states align their legal strategies, we can expect a surge in multi-state coalitions. These coalitions possess more leverage than any single state, making it more likely that companies will agree to lower prices globally rather than fighting dozens of individual lawsuits.
Frequently Asked Questions
How does a settlement lower the cost of my medication?
Settlements often include mandates that the company stop blocking generic competitors or agree to cap out-of-pocket costs for consumers.
What is the difference between a generic drug and a brand-name drug?
Generic drugs contain the same active ingredients as brand-name drugs and are bioequivalent, but they are typically much cheaper because the generic manufacturer did not have to fund the original research and development.
Why do some drug prices increase so suddenly?
Prices often spike when a company achieves a monopoly, faces no competition, or utilizes “patent thickets” to maintain cheaper alternatives off the market.
Join the Conversation
Do you believe the government should have more power to regulate drug prices, or should the free market decide? Share your thoughts in the comments below or subscribe to our newsletter for more deep dives into healthcare affordability.
